A
Antengene
Antengene is a biopharmaceutical company
About Antengene
Antengene is a biopharmaceutical company focused on developing and commercializing innovative oncology and immunology therapies. The company serves patients with cancer and viral diseases, operating primarily in the Asia-Pacific region and expanding globally. Antengene's business model involves research and development of novel drugs, conducting clinical trials, and partnering with other pharmaceutical companies for commercialization. Revenue is generated through the sale of proprietary drugs and licensing agreements. The company leverages its strong pipeline of clinical-stage assets and strategic collaborations to address unmet medical needs in oncology and immunology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Huangpu, China
- Employees
- 59
- Open positions
- None listed
- Dealroom signal
- 64.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Nov 2020 | $340M | $340M | Undisclosed | — |
| SERIES COther financing | Jul 2020 | $97M | $600M | Boyu Capital · Qiming Venture Partners · GIC · GL Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Antengene is 1.7K monthly website visits, down 10.5% over the last three months. Antengene's team declined 4.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Qiming Venture Partners
Hg Capital
TF Capital
Boyu Capital
FountainVest Partners
Taikang Life Insurance
Celgene
WuXi Healthcare Ventures
Series B and later3 investors entered at this stage
Fidelity Investments
GIC
GL Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antengene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antengene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.